Expression of Syndecan -1 and Cyclin D1 in Salivary Glands Adjacent to Salivary Gland Tumors

Volume 11 , Issue 2 , August 2024 , Pages 45-52

Authors

Ban F Ibraheem 1

1 University of Sulaimani

DOI logo 10.17656/sdj.10191

Keywords

Abstract

Objective: Investigating the stain localization, inflammation, pattern of distribution, and stain intensity of syndecan -1 and cyclin D1 in salivary gland tissue bordering different salivary gland tumors.
Methods: Twenty-six formalin-fixed paraffin-embedded blocks of salivary gland tissue adjacent to previously diagnosed salivary gland tumors were collected and stained with anit-syndecan-1 and anti-cyclin D1 antigens. Data were analyzed using Fisher's exact test, while Spearman’s rho test was used to correlate both markers' expressions.
Results: This study included 26 patients, six males and twenty females, with a median age of 50. The most prevalent site was the minor salivary gland (14 cases). Syndecan-1 accounted for the majority of cytoplasmic expression in various salivary gland components. Tumor type showed a statistical impact on the marker’s expression of both mucous and serous acini, respectively (p=0.000, p=0.010). There was a statistically significant difference in grading of malignancy in the expression of myoepithelial cells (p=0.028), interlobular duct (p=0.005), and serous acini (p=0.023). Cyclin D1 expression was mainly nuclear. A significant relation was found between tumor grading and the marker expression in all salivary gland components. A significant correlation was found between the expression of the two markers.
Conclusions: Syndecan-1 and cyclin D1 showed a significant combined expression in salivary tissue adjacent to different salivary gland tumors. This implies an essential influence of molecular changes in the tumor microenvironment and possible future recurrence and metastasis of malignancies. This could highlight the significance of these markers as an indicator of diagnosis, prognosis, and treatment strategies.

References

  1. Cunha JLS, Coimbra ACP, Silva JVR, Nascimento IS Do, de Andrade ME, de Oliveira CR, et al. Epidemiologic analysis of salivary gland tumors over a 10-years period diagnosed in a Northeast Brazilian population. Med Oral Patol Oral y Cir Bucal. 2020;25(4):e516-22.
  2. Vasconcelos AC, Nör F, Meurer L, Salvadori G, Souza LB, Vargas PA, et al. Clinicopathological analysis of salivary gland tumors over a 15-year period. Braz Oral. 2016;30:e2
  3. Tenório J da R, da Silva LP, Xavier MG de A, Santana T, do Nascimento GJF, Sobral APV. Differential expression of cyclooxygenase-2 and cyclin D1 in salivary gland tumors. Eur Arch Oto-Rhino-Laryngology. 2018;275(9):2341-7.
  4. Mise I. Value of immunohistochemical determination of syndecan-1 in breast cancer. Libr Oncol. 2021;49(1):29-38.
  5. Couchman JR. Syndecan-1 (Cd138), carcinomas and emt. Int J Mol Sci. 2021;22(8):4227.
  6. Alaeddini M, Yazdani F, Etemad-Moghadam S. Stromal and epithelial syndecan-1 expression in benign and malignant salivary gland tumors: which is more reflective of behavior? Braz J Otorhinolaryngol. 2021;87:171-77.
  7. Mohammad DN, Ibraheem BF, Mahmood DK. Expression of Syndecan-1 and Cyclin D1 in salivary gland tumors in relation to clinicopathological parameters. Int J Gen Med. 2023;16:823-3
  8. Palaiologou M,Delladetsima I, Tiniakos D. CD138 (syndecan-1) expression in health and disease. Histol Histopathol. 29(2):177-89.
  9. Zhou CX, Gao Y. Aberrant expression of β-catenin, Pin1and cylin D1 in salivary adenoid cystic carcinoma: Relation to tumor proliferation and metastasis. Oncol Rep. 2006;16(3):505-11.
  10. Abid AM, Merza MS. Immunohistochemical expression of Cyclin D1 and NF-KB p65 in oral lichen planus and oral squamous cell carcinoma (Comparative study). J Bagh Coll Dentistry 2014;26(1):80-7.
  11. Jour G, West K, Ghali V, Shank D, Ephrem G, Wenig BM. Differential expression of p16INK4A and cyclin D1 in benign and malignant salivary gland tumors: a study of 44 cases. Head Neck Pathol. 2013;7(3):224-31.
  12. Moghadam SA, Jahani N, Mokhtari S. Immunohistochemical analysis of cyclind1 expression in salivary gland tumors. Oral Surg Oral Med Oral Pathol Oral Radiol. 2015;119(3):e174.
  13. Wang C, Li Z, Fu M, Bouras T, Pestell RK. Signal Transduction Mediated by Cyclin D1: from Mitogens to Cell Proliferation: A Molecular Target with Therapeutic Potential. In: Kumar R, editor. Molecular Targeting and Signal Transduction. Boston, MA: Springer US; 2004. p. 217-37.
  14. Athanasiou E, Kaloutsi V, Kotoula V, Hytiroglou P, Kostopoulos I, Zervas C, et al. Cyclin D1 overexpression in multiple myeloma: A morphologic, immunohistochemical, and in situ hybridization study of 71 paraffin-embedded bone marrow biopsy specimens. Am J Clin Pathol. 2001;116(4):535-42.
  15. Uchimaru K, Taniguchi T, Yoshikawa M,Asano S,Arnold A,Fujita T et al. Detection of cyclin D1 (bcl-1, PRAD1) overexpression by a simple competitive reverse transcription–polymerase chain reaction assay in t(11;14)(q13;q32)-bearing B-cell malignancies and/or mantle cell lymphoma. Blood. 1997;89(3):965-74.
  16. Ibraheem BF, Mohammad DN, Hamied MA. Expression of β-catenin in minor salivary glands adjacent to oral squamous cell carcinoma. Sulaimani Dent J. 2020;7(2):9-15.
  17. Hamied MA. Immunohistochemical Expression of BubR1 and Telomerase in Minor Salivary Gland Tissue Adjacent to Oral Squamous Cell Carcinoma. Sulaimani Dent J. 2021;8(1):44-54.
  18. Lydiatt WM, Anderson PE, Bazzana T, Casale M, Hughes CJ, Huvos AG, et al. Molecular support for field cancerization in the head andneck. Cancer. 1998;82(7):1376-80.
  19. Athiasekar AC, Mathew DG, Jaish Lal MS. Arul Prakash AA, Goma Kumar KU. Oral field cancerization and its clinical implications in the management in potentially malignant disorders. J Pharm Bioallied Sci. 2017;9(1):23-5.
  20. Steuer CE, Hanna GJ, Viswanathan K, et al. The evolving landscape of salivary gland tumors. CA Cancer J Clin. 2023;73(6):597-619.
  21. Alraddadi T, Aldhahri S, Alharbi J, Malas M, Islam T, Altuwaijri A, et al. Predictors for salivary gland cancer recurrence at two tertiary hospitals in Saudi Arabia. Cureus. 2019;11(7):e5288.
  22. Fares J, Fares MY, Khachfe HH, Salhab HA, Fares Y. Molecular principles of metastasis: a hallmark of cancer revisited. Signal Transduct Target Ther. 2020;5(1):28.
  23. Dvorak HF, Weaver VM, Tlsty TD, Bergers G. Tumor microenvironment and progression. J Surg Oncol. 2011;103(6):468-74.
  24. Guo S, Wu X, Lei T, Zhong R, Wang Y, Zhang L, et al. The Role and Therapeutic Value of Syndecan-1 in Cancer Metastasis and Drug Resistance. Front Cell Dev Biol. 2022;9:784983.
  25. Scarini JF, de Lima-Souza RA, Lavareze L, Ribeiro de Assis MCF, Damas II, Altemani A, et al. Heterogeneity and versatility of the extracellular matrix during the transition from pleomorphic adenoma to carcinoma ex pleomorphic adenoma: cumulative findings from basic research and new insights. Front Oral Hea. 2023;4:1-10.
  26. Mayer M, Nachtsheim L, Hoffmann F, Von Eggeling F, Guntinas-Lichius O, Prinz J, et al. CD138 is expressed in different entities of salivary gland cancer and their lymph node metastases and therefore represents a potential therapeutic target. Int J Mol Sci. 2022;23(16): 9037.
  27. Gerber TS, Bartsch F, Wagner DC, Schindeldecker M, Heuft LK, Roth W, et al. Clinicopathological significance of syndecan-1 in cholangiocarcinoma: a study based on immunohistochemistry and public sequencing data. J Clin Med. 2021;10(13):2745.
  28. Singh N, Baby D, Rajguru JP, Patil PB, Thakkannavar SS, Pujari VB. Inflammation and cancer. Ann Afr Med. 2019;18(3):121-12
  29. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140(6):883-99.
  30. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420(6917):860-7.
  31. Greten FR, Grivennikov SI. Inflammation and cancer: triggers, mechanisms, and consequences. Immunity. 2019;51(1):27-41.
  32. Whiteside TL. The tumor microenvironment and its role in promoting tumor growth. Oncogene. 2008;27(45):5904-12.
  33. Maiorino L, Daßler-Plenker J, Sun L, Egeblad M. Innate immunity and cancer pathophysiology. Annu Rev Pathol Mech Dis. 2021;17:425-57.
  34. Abbate V, Barone S, Troise S, Laface C, Bonavolontà P, Pacella D, et al. The combination of inflammatory biomarkers as prognostic indicator in salivary gland malignancy. Cancers (Basel). 2022;14(23):5934.
  35. Kim SW, Roh J, Park CS. Immunohistochemistry for pathologists: protocols, pitfalls, and tips. J Pathol Transl Med. 2016;50(6):411-18.
  36. Yue LE, Samankan S, Liu X, Sharif KF, Everest S, Singh T, et al. Ten patients with high-grade transformation of acinic cell carcinomas: Expression profiling of β-catenin and cyclin D1 is useful. Pathol Res Pract. 2020;216(2):152767.
  37. Malik SM,Niazi Z, Ali Khan M, Hashmi SN. Cyclin D1 Protein Expression in Various Grades of Salivary Mucoepidermoid Carcinoma. Pak Armed Forces Med J. 2019;69(4):920-5.
  38. Tenório J da R, da Silva LP, Xavier MG de A, Santana T, do Nascimento GJF, Sobral APV. Differential expression of cyclooxygenase-2 and cyclin D1 in salivary gland tumors. Eur Arch Oto-Rhino-Laryngology. 2018;275(9):2341-7.
  39. Montalto FI, De Amicis F. Cyclin D1 in cancer: a molecular connection for cell cycle control, adhesion and invasion in tumor and stroma. Cells. 2020;9(12):2648.
Statistics
  • Article view644
  • Downloads4
  • Published at1 August 2024

  • RIS
  • BibTeX
  • EndNote
  • Mendeley
  • APA (7th edition)
  • MLA (9th edition)
  • Chicago
  • Harvard
  • IEEE
  • Vancouver